Epidemiology and Clinical Characteristics of Non-Hodgkin Lymphoma in Mexico.

Autor:	Hernandez-Ruiz E; Servicio de Hematologia, Hospital Regional de Alta Especialidad, de Oaxaca, Oaxaca, Mexico.; Servicio de Hematologia, Centro Medico Nacional '20 de Noviembre', ISSSTE, Mexico City, Mexico.; Servicio de Hematologia, Hospital Regional Presidente Juarez de Oaxaca, ISSSTE, Oaxaca, Mexico., Alvarado-Ibarra M; Servicio de Hematologia, Centro Medico Nacional '20 de Noviembre', ISSSTE, Mexico City, Mexico., Juan Lien-Chang LE; Servicio de Hematologia, Unidad de Oncologia y Servicios de Salud del Estado de Puebla, Puebla, Mexico., Banda-Garcia L; Servicio de Hematologia, Hospital General de Zona No. 11 de Xalapa, Veracruz, Mexico., Aquino-Salgado JL; Servicio de Hematologia, Hospital Regional de Alta Especialidad, de Oaxaca, Oaxaca, Mexico., Barragan-Ibanez G; Servicio de Hematologia, Hospital Regional de Alta Especialidad, de Oaxaca, Oaxaca, Mexico., Ramirez-Romero EF; Servicio de Hematologia, Hospital Regional Presidente Juarez de Oaxaca, ISSSTE, Oaxaca, Mexico., Nolasco-Cancino C; Servicio de Hematologia, Hospital Regional Doctor Juan Graham Casasus de Villahermosa, Tabasco, Mexico.; Servicio de Hematologia, Hospital CERACOM, Villahermosa, Tabasco, Mexico., Herrera-Olivares W; Servicio de Hematologia, Hospital Regional de Puebla, ISSSTE, Puebla, Mexico., Morales-Adrian JJ; Servicio de Hematologia, Hospital Regional de Merida, ISSSTE, Yucatan, Mexico., Paredes-Lozano EP; Servicio de Hematologia, Hospital Regional 1° de Octubre ISSSTE, Mexico City, Mexico., Espitia-Rios ME; Servicio de Hematologia, Centro Medico Nacional '20 de Noviembre', ISSSTE, Mexico City, Mexico., Gonzalez Lopez-Elizalde MM; Servicio de Hematologia, Hospital H+ de Queretaro, Queretaro, Mexico., Lopez-Arroyo JL; Servicio de Hematologia, Hospital General B de Ciudad Juarez, Chihuahua, Mexico., Trejo-Gomora JE; Servicio de Hematologia, Hospital San Angel Inn Universidad, Mexico City, Mexico., De la Pena-Celaya JA; Servicio de Hematologia, Centro Medico Nacional '20 de Noviembre', ISSSTE, Mexico City, Mexico., Alvarez-Vera JL; Servicio de Hematologia, Centro Medico Nacional '20 de Noviembre', ISSSTE, Mexico City, Mexico., Arana-Luna LL; Servicio de Hematologia, Centro Medico Nacional '20 de Noviembre', ISSSTE, Mexico City, Mexico., Martinez-Rios A; Servicio de Hematologia, Hospital Regional Ignacio Zaragoza ISSSTE, Mexico City, Mexico., Resendiz-Olea R; Servicio de Hematologia, Hospital Regional Ignacio Zaragoza ISSSTE, Mexico City, Mexico., Rodriguez-Velasquez LJ; Servicio de Hematologia, Hospital Regional de Alta Especialidad, de Oaxaca, Oaxaca, Mexico., Zapata-Canto N; Instituto Nacional de Cancerologia, Mexico City, Mexico., Perez-Zuniga JM; Servicio de Hematologia, Centro Medico Nacional '20 de Noviembre', ISSSTE, Mexico City, Mexico.; Servicio de Hematologia, Hospital Regional Ignacio Zaragoza ISSSTE, Mexico City, Mexico.
Jazyk:	angličtina
Zdroj:	World journal of oncology [World J Oncol] 2021 Feb; Vol. 12 (1), pp. 28-33. Date of Electronic Publication: 2021 Feb 24.
DOI:	10.14740/wjon1351
Abstrakt:	Background: There is no epidemiological registry in Mexico. The information about the epidemiology in our country is obtained by these types of studies, such as multicentric studies. A lot of improvements in the survival in non-Hodgkin lymphoma patients had occurred in the last 20 years. The access to treatment in these types of pathology could change the prognostic factors in Mexican Mestizos patients. The primary objective of the study was to learn what the most frequent histological varieties of non-Hodgkin lymphoma in Mexico are. The secondary objectives included clinical characteristics, treatments used, treatment response, disease-free survival and overall survival. Methods: A retrospective, descriptive study of consecutive cases was carried out in 14 hospitals across 14 Mexican states with patients diagnosed with non-Hodgkin lymphoma using the World Health Organization (WHO) 2008 criteria. Inclusion criteria included: ≥ 18 years of age, male or female, any clinical stage at diagnosis, who had received any chemotherapy regimen, with a known outcome. Descriptive statistics was performed for all variables, and survival was assessed using Kaplan-Meier curves. Results: Totally, 609 patients were enrolled, of which 545 were B-cell lymphomas and 64 were T-cell lymphomas. Median ages were 61 and 50, respectively. B-cell lymphomas were more common in males with 52.1%, and 65.5% of T-cell lymphomas occurred in females. For B-cell lymphomas, the two most frequent histological subtypes were diffuse large B-cell lymphoma in 63.9%, followed by follicular lymphoma at 18%. Meanwhile, 50% of T-cell lymphomas were of the T/natural killer (NK) subtype, and 87.1% of the patients received a CHOP-like regimen. Radiotherapy was given to 31% of B-cell Lymphomas and 46.9% of T-cell lymphomas. Overall survival at 9 years was 84.6% for B-cell lymphomas, and 73.4% for T-cell lymphomas. Conclusions: Diffuse large B-cell lymphoma constitutes the most frequent subtype for B-cell lymphomas in Mexico. The most frequent T-cell lymphoma is the NK/T histological subtype. Competing Interests: The authors have no potential conflict of interest to disclose. (Copyright 2021, Hernandez-Ruiz et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu